Company Expanding to Meet the Global Demands for Innovative Drug Delivery
GLEN ROCK, Pa., Sept. 19 /PRNewswire/ -- ARx(TM), LLC, a subsidiary of Adhesives Research, is pleased to announce the official opening of its new state-of-the-art pharmaceutical manufacturing facility just eighteen months after breaking ground.
The new 25,000 square-foot facility is designed to manufacture dissolvable film, transdermal, and buccal drug delivery systems for over-the-counter (OTC), prescription, and biopharmaceutical products. The globally-compliant facility triples ARx's manufacturing capacity and laboratory space to support its rapidly growing portfolio of projects and clients.
ARx currently supports multiple commercial thin film products sold in the United States, Canada and Latin America, including Novartis Consumer Health's Triaminic(R) Thin Strips(TM) pediatric and infant cough and cold products, Theraflu(R) Thin Strips(TM) cold and flu products, and Gas-X(R) Thin Strips(TM) anti-gas relief products. The current facility and evolving pipeline further supports ARx's market leadership by quadrupling potential strip output to over 1.4 billion strips per year.
"We have used our knowledge and twenty-plus years of experience in the pharmaceutical industry to build a modern, globally-compliant facility that allows us to streamline the manufacturing process and create an efficient and flexible process for our clients," said Beth Vondrak, ARx Vice President and General Manager.
Dissolvable thin film technology gives consumers a choice of delivery
options for taking OTC and prescription medicines. The key benefits of the
technology include quick and precise dosing, convenience and portability.
These films have proven to be very popular for the pediatric population,
who usually ingest the entire thin film dose (versus liquids that can be
expelled from the mouth), as well as with geriatric patients and othe
|SOURCE ARx, LLC|
Copyright©2007 PR Newswire.
All rights reserved